Cancer clinical trials in the region Île-de-France

417 currently recruiting clinical trials

Looking for clinical trials?

Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:

Create your account
Copy-paste your latest medical report
Our AI-based assistant does the rest for you

Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:

Create your account
and find trials relevant to your profile

Phase 2 Breast cancer #NCT05955170 #2022-500743-20-00

[TUC-TOC] TUCATINIB en association avec l'ETOPOSIDE oral et le TRASTUZUMAB chez les patientes atteintes d'un cancer du sein métastatique HER2+

HER2 Positive Metastatic 1 Chemotherapy Targeted therapy Chemotherapy Targeted therapy

Institut Curie - Paris (Paris), Institut Curie (Saint Cloud) - Hôpital René Huguenin (Saint-Cloud)

Institut Curie

Phase 2 Lung cancer #NCT05498428 #2023-505065-91-00

[PALOMA-2] Étude de l'AMIVANTAMAB chez des patients atteints d'un cancer du poumon non à petites cellules muté EGFR - Cohorte 4

NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic 1 Bispecific T-cell engager antibodies

Gustave Roussy (Villejuif), Institut Curie - Paris (Paris)

Janssen

Phase 2 Lymphoma #NCT05963074 #2023-504044-34-00

[TAILOR] Étude visant à personnaliser les schémas thérapeutiques à base d'IBRUTINIB pour les participants atteints de leucémie lymphoïde chronique/lymphome lymphocytaire à petits lymphocytes non traités auparavant

B cell lymphoma Lymphocytic lymphoma None None Systemic Treatment-Naive

Hôpital Pitié Salpêtrière - AP-HP (Paris)

Janssen

Phase 2 Pancreas cancer #NCT06172478 #2023-507641-29-00

[HERTHENA-PanTumor01] Etude sur HER3-DXd chez des sujets atteints de tumeurs solides localement avancées ou métastatiques

Adenocarcinoma Locally Advanced Metastatic 1

Systemic Treatment-Naive

Gustave Roussy (Villejuif)

Daiichi Sankyo

Phase 2 Breast cancer #NCT05215106 #2024-512082-14-00

[POP-DURVA] Étude du DURVALUMAB (MEDI 4736) préopératoire de courte durée chez des patientes atteintes d'un cancer du sein triple négatif de petite taille

HER2 Negative HR Negative Localized None Systemic Treatment-Naive

Surgery Immunotherapy Chemotherapy Targeted therapy Car-T Bispecific T-cell engager antibodies Antibody Drug Conjugates (ADC) Radiotherapy

Gustave Roussy (Villejuif)

Gustave Roussy, Campus du cancer, Grand Paris

Phase 2 Kidney cancer #NCT05865730 #2024-516711-24-00

Étude d'Oncobax®-AK chez des patients atteints de tumeurs solides avancées

Clear cell carcinoma Locally Advanced Metastatic

Gustave Roussy (Villejuif)

EverImmune

Phase 2 Lung cancer #NCT05609578 #2023-503714-77-00

Essai de phase 2 sur les thérapies combinées avec l'ADAGRASIB chez des patients atteints d'un cancer du poumon non à petites cellules avancé avec mutation KRAS G12C - Cohorte C

NSCLC (Non-Small Cell Lung Cancer) Non-squamous NSCLC Locally Advanced Metastatic KRAS G12C PDL1 Positive (1% <= X < 25%) PDL1 Positive (25% <= X < 50%) None Immunotherapy Chemotherapy

Targeted therapy Targeted therapy

Centre Hospitalier Intercommunal Créteil (Créteil Cedex), Hôpital Tenon AP-HP (Paris ), Hôpital Foch (Suresnes)

Mirati Thérapeutique Inc.

Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer #NCT06760819 #2024-517419-62-00

[panSOHO] Etude sur l'efficacité du BAY2927088 et sur son innocuité chez les participants atteints d'une tumeur solide présentant des mutations activatices d'HER2

Stomach Oesogastric junction Esophagus Adenocarcinoma Intrahepatic cholangiocarcinoma Extrahepatic cholangiocarcinoma Ampullary carcinoma Gastrointestinal stromal tumor Squamous cell carcinoma Other HER2 Positive Locally Advanced Metastatic Metastatic Castration-resistant HER2 1

Systemic Treatment-Naive

Gustave Roussy (Villejuif)

Bayer

Phase 2 Breast cancer #NCT06172478 #2023-507641-29-00

[HERTHENA-PanTumor01] Etude sur HER3-DXd chez des sujets atteints de tumeurs solides localement avancées ou métastatiques

HER2 Negative HR Positive Locally Advanced Metastatic 1 Chemotherapy Targeted therapy Hormone therapy

ALK BRAF EGFR HER2 KRAS G12C MET NTRK-1/2/3 RET ROS-1 Systemic Treatment-Naive

Gustave Roussy (Villejuif)

Daiichi Sankyo

Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT05503797 #2024-513578-23-00

Etude visant à évaluer l'efficacité et la sécurité du FORE8394 chez des participants atteints d'un cancer présentant des altérations du gène BRAF - Sous protocole A

Locally Advanced Metastatic BRAF 1 2 3 or more

KRAS G12C KRAS non G12C NRAS HRAS Systemic Treatment-Naive

Gustave Roussy (Villejuif), Hôpital Pitié Salpêtrière - AP-HP (Paris)

Fore Biotherapeutics